

L Number	Hits	Search Text	DB	Time stamp
1	846	((514/2,13-20).ccls. and @pd>20030706	USPAT; US-PGPUB	2004/01/21 12:56
2	6259	valboropro\$ or boronic or boropro\$ or boro adj (pro! or proline or prolyl or prolanyl) or dppiv or dpiv or (dpp! or dp!) adj iv! or dipeptidyl\$ or fap adj alpha or fapalpha or fibroblast adj activation adj protein	USPAT; US-PGPUB	2004/01/21 13:03
3	34	((514/2,13-20).ccls. and @pd>20030706) and (valboropro\$ or boronic or boropro\$ or boro adj (pro! or proline or prolyl or prolanyl) or dppiv or dpiv or (dpp! or dp!) adj iv! or dipeptidyl\$ or fap adj alpha or fapalpha or fibroblast adj activation adj protein)	USPAT; US-PGPUB	2004/01/21 12:59
4	35	(valboropro\$ or boronic or boropro\$ or boro adj (pro! or proline or prolyl or prolanyl) or dppiv or dpiv or (dpp! or dp!) adj iv! or dipeptidyl\$ or fap adj alpha or fapalpha or fibroblast adj activation adj protein) with (cancer\$ or tumor\$ or tumour\$ or carcinoma\$ or sarcoma\$ or melanoma\$ or metasta\$ or angiogen\$ or fibrosarcom\$ or osteosarcom\$ or stromal adj fibroblast) and @pd>20030706	USPAT; US-PGPUB	2004/01/21 13:06

checked 13.04
JRN
1-26-2004

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 199723302 B2
(10) Patent No. 729369

(54) Title
Isolated dimeric fibroblast activation protein alpha, and uses thereof

(51)⁷ International Patent Classification(s)
C07K 014/435 C12Q 001/00
A61K 038/43 G01N 033/50
C12N 015/52

(21) Application No: **199723302** (22) Application Date: **1997.03.12**

(87) WIPO No: **WO97/34927**

(30) Priority Data

(31) Number	(32) Date	(33) Country
08/619280	1996.03.18	US

(43) Publication Date : **1997.10.10**

(43) Publication Journal Date : **1997.12.04**

(44) Accepted Journal Date : **2001.02.01**

(71) Applicant(s)
Ludwig Institute for Cancer Research; Boehringer Ingelheim International GmbH

(72) Inventor(s)
Rainer Zimmerman; John E. Park; Wolfgang Rettig; Lloyd J. Old

(74) Agent/Attorney
CALLINAN LAWRIE, Private Bag 7, KEW VIC 3101



Intellectual Property Office of New Zealand
IP Summary Report

Page: 1 of 1
Date: 15 March 2001
Time: 09:49:28
(lrip02 3.00.02)

(51) Classification: A61K38/43	Status: 70 Accepted Client Ref: JP801966	335543 Version number: 5 IP type: Patent Convention
(22) NZ Filing date: 03 May 1999 (30) Priority Data: (31) 96 619280 (32) 18 March 1996 (33) US (71) Applicants: LUDWIG INSTITUTE FOR CANCER RESEARCH, 605 Third Avenue, New York, New York 10158, United States of America BOEHRINGER INGELHEIM INTERNATIONAL GmbH, D-6507 Ingelheim am Rhein, Federal Republic of Germany (72) Inventors: Zimmerman, Rainer Park, John E Old, Lloyd J Rettig, Wolfgang Contact: BALDWIN SHELSTON WATERS, Level 14, NCR House, 342 Lambton Quay, Wellington, New Zealand Primary Examiner: CLAIRE MCINNES Journal: 1461		(62) Divided out of: 331758 Divisional number(s): 509792 Date actions completed: Application Accepted: 15 March 2001 Next renewal date: 03 May 2003
Office title: Use of a collagen derivative as an fibroblast activation protein alpha (FAP-alpha) inhibitor (54) Applicant title: Isolated dimeric fibroblast activation protein alpha, and uses thereof (57) Abstract: Patent 335543 Use of an inhibitor of FAP-alpha activity which interacts with molecules having FAP-alpha activity, said inhibitor being a collagen derivative, in the manufacture of a medicament for treating a subject with a pathological condition characterized by abnormal FAP-alpha activity.		

**** End of report ****